Michael Brophy
Net Worth
Last updated:
What is Michael Brophy net worth?
The estimated net worth of Mr. Michael Brophy is at least $51,917,617 as of 31 Oct 2024. He owns shares worth $11,020,291 as insider, has earned $36,475,216 from insider trading and has received compensation worth at least $4,422,110 in Natera, Inc..
What is the salary of Michael Brophy?
Mr. Michael Brophy salary is $631,730 per year as Chief Financial Officer in Natera, Inc..
How old is Michael Brophy?
Mr. Michael Brophy is 45 years old, born in 1980.
What stocks does Michael Brophy currently own?
As insider, Mr. Michael Brophy owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Natera, Inc. (NTRA) | Chief Financial Officer | 68,851 | $160.06 | $11,020,291 |
What does Natera, Inc. do?
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Michael Brophy insider trading
Natera, Inc.
Mr. Michael Brophy has made 133 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,866 units of NTRA stock worth $235,956 on 31 Oct 2024.
The largest trade he's ever made was exercising 108,108 units of NTRA stock on 14 Sep 2018. As of 31 Oct 2024 he still owns at least 68,851 units of NTRA stock.
Natera key executives
Natera, Inc. executives and other stock owners filed with the SEC:
- Dr. Matthew Rabinowitz Ph.D. (52) Co-Founder & Executive Chairman
- Mr. Jonathan Sheena (52) Co-Founder & Director
- Mr. Michael Brophy (45) Chief Financial Officer
- Mr. Robert A. Schueren (63) Chief Operating Officer
- Mr. Steve Leonard Chapman (46) Chief Executive Officer, Pres & Director